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Abstract 
The study of apoptosis and proliferative activity in the thyroid gland (TG) tissue of 
patients with nodular goiter and autoimmune thyroiditis (NGAIT) and thyroid adenoma (TA) 
is based on the expression/density of Fas/FasL, BCL-2, p53, and Ki-67 markers assessment 
depending on the genetic polymorphisms of BCL-2 (rs17759659), CTLA-4 (rs231775) and 
APO-1/Fas (rs2234767) genes. 
Several mechanisms of thyroid cells' programmed killing are activated in NGAIT and 
TA with domination of Fas-induced apoptosis, which strongly associates with the BCL-2 
gene's (rs17759659) promoter (F=25.33; p<0.001) and almost six fold weaker associates with 
the CTLA-4 gene's (rs231775) promoter (F=4.23, p=0.017). Factors that decrease the 
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likelihood of NGAIT and TA regardless of the CTLA-4 (rs231775) and APO-1/Fas 
(rs2234767) genes' genotypes are the high Ki-67 density and reduction of cells containing p53 
or BCL-2 proteins (OR=0.07-0.17; 95% CI OR: 0.03-0.36; p<0.001, and OR=0.08-0.11; 95% 
CI OR: 0.02-0.31; p<0.001, respectively). High expression of surface Fas and FasL in 
lymphoid infiltration and destruction of thyroid cells (stronger in GG-genotype carriers of the 
BCL-2 gene by 18.54% (pAA=0.043) and 36.18% (pAG=0.018), respectively) indicates the 
initiation of the external pathway of apoptosis through the caspase mechanism (effector 
caspase- 8). 
Key words: nodular goiter with autoimmune thyroiditis, thyroid adenoma, 
proliferation, apoptosis, APO-1 / FAS, CTLA-4 and BCL-2 genes polymorphisms. 
 
1. Introduction 
Multinodular goiter is the most common disorder of the thyroid gland because of the 
genetic heterogeneity of follicular cells and apparent acquisition of new cellular festures that 
become inheritable [1]. The etiology of nodular goiters is not completely understood. Age-
related increase in thyroid weight and nodularity may be secondary to iodine deficiency rather 
than an inherent ageing of thyroid gland [2, 3]. Endemic goiters secondary to iodine 
deficiency are associated with increased formation of hyperplastic nodules partly because of 
overstimulation of thyroid gland with thyroid stimulating hormone [4]. Another cause of 
nodular goiter is Hashimoto’s disease [5-7]. Autoimmune thyroiditis (AIT) is a chronic 
autoimmune disorder characterized by lymphocytic inflammation of thyroid gland. The 
triggers for this autoimmune response appear to be both humoral and cellular, with complex 
etiology involving genetic and environmental factors [8]. Individuals with Hashimoto's 
thyroiditis have an increased risk for developing other autoimmune disorders, including 
rheumatoid arthritis, Addison's disease, type 1 diabetes mellitus, multiple sclerosis, and 
pernicious anemia [8, 9]. 
The interaction of Fas with its ligand FasL regulates a number of physiologic and 
pathologic processes of cell death. Triggering of Fas contributes to the regulation of immune 
response and tissue homeostasis, as well as to the immunologic clearance of virus or tumor 
cells. The destructive processes overcome the potential capacity of thyroid replacement, 
estimated as about 5- to 10-fold in a lifetime [10]. Apoptosis has been occasionally observed 
in histologic sections of normal thyroid. However, apoptotic cell death is abnormally 
accelerated during the pathologic phases, leading to clinical hypothyroidism in AIT. IL-1P, 
abundantly produced in TG, induces Fas expression in normal thyrocytes, and crosslinking of 
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Fas results in massive thyrocytes apoptosis. The ligand for Fas is shown to be constitutively 
expressed in both normal and AIT thyrocytes and is able to kill Fas-sensitive targets. 
Exposure to IL-induced thyrocytes apoptosis, which is prevented by antibodies that block Fas, 
suggesting that IL-induced Fas expression serves as a limited factor for thyrocytes 
destruction. Thus, Fas-FasL interactions within AIT thyrocytes may contribute to clinical 
hypothyroidism [10]. Majority of authors focused on the molecular markers of apoptosis and 
proliferation in the thyroid gland cancer and toxic goiter [11-13]. Variations in several genes 
have been studied as possible risk factors for Hashimoto thyroiditis. Most of the genetic 
variations that have been discovered are thought to have a moderate impact on an individual 
overall risk of developing this condition [14-22]. 
The aim of this study is to find possible associations of BCL-2 (rs17759659), CTLA-4 
(rs231775), APO-1/Fas (rs2234767) genes' polymorphisms with activity of proliferation and 
apoptosis (expression/density of Fas/FasL, BCL-2, p53, and Ki-67) in thyroid tissue of 
patients with nodular forms of goiter combined with autoimmune thyroiditis and thyroid 
adenoma. 
2. Material and methods 
2.1.  Subjects 
One hundred and twenty-five women with NGAIT underwent examination during 
2013-2016, based on Chemivtsi Regional Hospital, Ukraine. The age of patients ranged from 
23-72 years (mean age (±SD) 43.7±7.11). Diagnosis is primarily based on clinical and 
laboratory examinations (thyroid peroxidase antibodies (TPOAb) - 60-250 U/ml, 
thyroglobulin antibodies (TgAb) - 60-500 U/ml, thyroid-stimulating hormone (TSH) - 4.10 
IU/l, thyroid sonography, and histologic confirmation after surgery). Control group included 
25 healthy female donors of respective age and socio-economic status. 
2.2.  Tissue samples collection and evaluation 
During surgery, thyroid tissue was collected for immunohistochemical studies no later 
than 30 minutes after the intervention. In patients with TA, the unchanged tissue of the TG 
lobe and adenomatous tissue was taken, too. Additionally, in AIT patients the tissue from both 
lobes and from the isthmus was taken. Pieces of tissue weighing 100-300 mg were freezed 
and immediately transported and cut into 4-6 pieces weighing 50-70 mg each. 
Tissue bioptates underwent homogenization with further thyrocytes' cell suspension 
coloring with monoclonal antibodies (MAbs) to membrane receptors and intracellular 
proteins. Following MAbs panels were used: Mouse Human Ki-67 FITC Clone MIB-1; Anti-
p53 Protein Monoclonal Antibody, FITC Conjugated, Clone DO- 7; Mouse Anti-Human 
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Apoptosis Regulator BCL-2 (BCL2) Monoclonal, Unconjugated, Clone 124 antibody; Mouse 
Anti-Human CD95 Monoclonal Antibody, Unconjugated, Clone FAS 18; Mouse Anti-Human 
CD95L Monoclonal Antibody, Unconjugated, Clone NOK-1 (Dako Denmark A/S). 
The density of membrane (intracellular) receptors (proteins) expression was evaluated 
in standard units (s.u.) according to the mean fluorescence intensity (MFI), which was 
proportional to the channel number measured in logarithmic mode. 
While counting cells we evaluated proliferation and apoptosis indices in study areas, 
using gating (Fig. 1), selecting the window with cells under 25 microns. 
Fig. 1: Histogram of the thyroid tissue heterogeneous suspension with limited gating 
area (A) 
 
The number of cells, density of superficial (Fas, FasL) and intracellular proliferation, 
and apoptosis markers (Ki-67, BCL-2, p53) were determined. Phenotyping was performed on 
flow cytofluorimeter (FACS Calibur, BD Biosciences) counting 100,000 events in each 
sample, calculating the relative number of cells, and measuring the density/expression of 
receptors (proteins) in cells or groups of cells. Digital data (histograms) were analyzed in 
CXP ver. 2.2 software. 
2.3. Genotyping of SNPs 
DNA extraction was performed using Thermo Scientific Gene JET Genomic DNA 
Purification kit (#K0721, Thermo Fisher Scientific), with overnight incubation with 
Proteinase K for complete lysis of the cells. Purified DNA was diluted in Elution Buffer and 
the quality control was performed on Nano drop 2000C. Only samples that yield at least 15 
ng/^l and had A (260/280) between 1.7 and 2.0 were used for genotyping. The DNA was 
liquated; the stock was stored at -20oC, one aliquot at +4oC until use. All samples were diluted 
with Nuclease-free water to 2 ng/^l for normalization purpose. TaqMan technique was applied 
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to genotype selected SNPs. Reference SNP ID numbers from dbSNP were used for 
polymorphism notation. TaqMan SNP Genotyping Assays (40*) (4351379, Thermo Fisher 
Scientific) were used for the testing (table 1). 
 
Table 1: Analyzed SNP context sequences 
SNP Assay ID* Context Sequence 
rs231775 
(CTLA4) C 2415786 20 
GCACAAGGCTCAGCTGAAC- 
CTGGCT[A/G]CCAGGACCTGGCCCTGCACTCTCCT 
rs17759659 
(BCL-2) C33628167_10 
TCTTCTTACCAAAGATTCACAA- TAC [A/G] 
GTGTTGATGGGAACGTGACCTAGTT 
rs2234767 
(Fas) C12123966_10 
CAGAGTGT GT GCACAAGGCTGG- 
CAC[A/G]CCCAGGGTCTTCCTCATGGCACTAA 
 
Reaction volume was 5 ^l and included: 2.5 ^l of TaqMan Genotyping Master Mix 
(20x) (4371355, Thermo Fisher Scientific), 0.25 ^l of probes solution and 2.25 ^l of DNA 
solution. Genotyping procedure was done on Quant Studio 6 (Applied Biosystems, Thermo 
Fisher Scientific), 384-well block. The following amplification program was applied to 
produce the data: 
Note: * - applied for CTLA4 and Fas associated SNP; ** - for BCL-2 associated SNP. 
 
Quant Studio™ Real-Time PCR software (v. 1.3) was used for data acquisition and 
analysis. 
2.4. Statistical analysis 
Statistical analysis was performed using Statistica 7.0 (Stat Soft Inc.) software. 
Nominal data presented in the form of quantitative and percentages. All variables were 
normally distributed (Kolmogorov-Smirnov and Shapiro-Wilk tests). Each SNP was tested for 
deviation from Hardy-Weinberg equilibrium using the Online Encyclopedia for Genetic 
Epidemiology Studies (http://www.oege.org/software/hardy-weinberg.html). Pearson's 
criterion (x) was used for the genotypes distribution comparison. Analysis of qualitative data 
(categorical variables), risk of thyroid pathology development was assessed in binary logistic 
regression model using the relative risk (RelR), risk ratio (RR) and odds ratio (OR) with 95% 
HOLD (enzyme activation) 10 min 95oC  
Denaturation 15 sec 92oC 40*/60** 
Annealing / Extension 1 min 60oC cycles 
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confidence interval [95% CI], chi-square test (x2) (df=1). The difference was considered 
significant at p<0.05. 
3. Results and discussion 
3.1. Association of BCL-2 (rs17759659) gene’s polymorphism with proliferation 
and apoptosis activity in thyroid tissue 
Cell numbers and densities of the Fas, FasL, Ki-67, BCL-2, and p53 receptors 
considering the polymorphic variants of BCL-2 (rs17759659) gene are presented in table 2.  
 
Table 2: Cell numbers and densities of the Fas, FasL, Ki-67, BCL-2, and p53 receptors 
considering the polymorphic variants of BCL-2 (rs17759659) gene 
Indices 
Control 
(morphologically 
unaltered thyroid 
tissue), n=25 
BCL-2 genotypes 
AA, n=10 AG, n=110 GG, n=5 
Fas cells, % 0.79±0.04 
23.28±2.30 
p<0.001 
18.24±3.89 
p<0.001 
28.58±0.55 
p<0.001 
PAA=0.043 
PAG=0018 
Density of Fas 
receptors, s.u. 
13.82±0.40 6.75±1.25 
p<0.001 
7.38±1.12 
p<0.001 
6.45±0.95 
p<0.001 
FasL cells, % 3.85±0.16 11.93±1.71 
p=0.003 
10.57±1.34 
p=0.002 
12.14±1.45 
p=0.002 
Density of FasL 
receptors, s.u. 
11.13±0.85 7.57±0.96 
p=0.009 
8.29±0.64 
p=0.009 
7.34±0.39 
p=0.005 
p53 cells, % 64.14±1.89 67.79±1.27 59.47±7.0 68.02±1.52 
Density of p53 
protein, s.u. 
1.41±0.05 3.46±0.93 
p=0.035 
3.86±0.58 
p=0.004 
3.60±0.94 
p=0.028 
Ki-67 cells, % 
1.16±0.05 4.26±0.53 
p=0.001 
3.73±0.81 
p=0.001 
4.46±1.40 
p=0.026 
Density of Ki- 67 
protein, s.u. 
1.20±0.07 1.77±0.18 
p=0.006 
2.11±0.22 
p=0.005 
1.88±0.24 
p=0.012 
BCL-2 cells, % 
73.05±1.35 80.66±2.99 
p=0.027 
78.22±2.44 
p=0.055 
81.23±3.47 
p=0.037 
Density of BCL-2, 
s.u. 
3.86±0.16 7.18±1.57 
p=0.043 
6.62±1.07 
p=0.013 
7.40±1.49 
p=0.026 
Notes: 1. TG- thyroid gland; 2. p - reliability of index differences compared to those in 
the control group; pAA - reliability of index differences with carriers of AA-genotype; pAG - 
reliability of index differences with carriers of AG-genotype. 
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The number of immunoreactive cells expressing surface transmembrane protein Fas is 
18.54% (PAA=0.043) and 36.18% (pAG=0.018) higher in homozygous carriers of minor G-
allele of the BCL-2 gene than in main A-allele carriers (AA- and AG-genotypes, 
respectively). Significantly higher number of cells with Fas, FasL receptors, BCL-2, and Ki-
67 (р<0.055-0.001) observed in patients with thyroid pathology compared to control, whilst 
the density of Fas and FasL receptors was reliably lower than in control group (p<0.05), 
independent on the polymorphic variants of BCL-2 gene. The proliferation and apoptosis 
indices (Ki-67, BCL-2, and p53) in patients with thyroid pathology were reliably higher than 
in control (p<0.05). 
Univariate statistical analysis confirmed associations of the BCL-2 (rs17759659) 
gene's promoter with the number of cells expressing BCL-2 (F=7.25, p<0.001), p53 (F=10.58, 
p<0.001), Fas (F=25.33, p<0.001), FasL (F=7.18, p=0.001), Ki-67 (F=3.60, p=0.03), and with 
the density of the FasL receptors (F=9.74, p<0.001), as well as the protein proliferation 
marker Ki-67 (F=13.20, p<0.001). 
 
3.2. Associations of CTLA-4 (rs231775) gene’s polymorphism with proliferation 
and apoptosis activity in thyroid tissue 
Associations of cell numbers and densities of the Fas, FasL, Ki-67, BCL-2, and p53 
receptors with the polymorphic variants of CTLA-4 (rs231775) gene are shown in table 3. 
The density of intracellular protein Ki-67, which regulates the process of proliferation 
prevailed in the carriers of minor allele G (AG- and GG-genotypes) of the CTLA-4 gene 
compared to AA-genotype by 10% (p=0.033) and 11.5% (p=0.046), respectively. There were 
no reliable differences depending on the polymorphism of the CTLA-4 (rs231775) gene for 
the rest of the markers. The number of cells with receptors to Fas, FasL, and Ki-67, as well as 
the densities of p53, BCL-2, and Ki-67 prevailed over the control values (p<0.048-0.001). 
Univariate statistical analysis confirmed the associations of the CTLA-4 (rs231775) 
gene's promotor with the number of cells expressing p53 (F=8.35, p<0.001), Fas (F=4.23, 
p=0.017), FasL (F=5.61, p=0.005), Ki-67 (F=3.72, p=0.027) and the densities of Fas 
(F=17.17, p=0.001), BCL-2 (F=3.09, p=0.049), p53 (F=18.18, p<0.001), and Ki-67 proteins 
(F=56.26, p<0.001). 
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Table 3: Cell numbers and densities of the Fas, FasL, Ki-67, BCL-2, and p53 receptors 
considering the polymorphic variants of CTLA-4 (rs231775) gene 
Indices 
Control 
(morphologically 
unaltered thyroid 
tissue), n=25 
CTLA-4 genotypes 
AA, n=59 AG, n=62 GG, n=4 
Fas cells, % 0.79±0.04 18.62±4.20 
p<0.001 
18.90±4.02 
p<0.001 
12.81±1.25 
p<0.001 
Density of Fas 
receptors, s.u. 
13.82±0.40 7.48±1.32 
p=0.003 
7.10±1.80 
p=0.007 
10.12±1.05 
p=0.01 
FasL cells, % 3.85±0.16 10.64±1.40 
p=0.003 
10.81±1.26 
p=0.002 
8.52±1.18 
p=0.006 
Density of FasL 
receptors, s.u. 
11.13±0.85 8.20±0.61 
p=0.009 
8.15±0.57 
p=0.004 
8.19±0.47 
p=0.005 
p53 cells, % 64.14±1.89 61.46±4.39 58.39±5.26 65.03±2.90 
Density of p53 
protein, s.u. 
1.41±0.05 3.71±0.41 
p=0.002 
4.01±0.35 
p<0.001 
3.03±0.56 
p=0.008 
Ki-67 cells, % 
1.16±0.05 3.71±0.62 
p=0.005 
3.89±0.63 
p=0.004 
3.09±0.77 
p=0.019 
Density of Ki-67 
protein, s.u. 1.20±0.07 
2.0±0.08 
p<0.001 
2.20±0.11 
p<0.001 
pAA=0.033 
2.23±0.08 
p<0.001 
pAA=0.046 
BCL-2 cells, % 
73.05±1.35 78.49±3.24 78.40±2.36 77.21±4.82 
Density of BCL- 2, 
s.u. 
3.86±0.16 6.61±0.60 
p=0.004 
6.79±0.64 
p=0.003 
6.08±1.0 
p=0.037 
Notes: 1. TG– thyroid gland; 2. р – reliability of index differences compared to those 
in the control group; рАА – reliability of index differences with carriers of АА-genotype; рAG 
– reliability of index differences with carriers of AG-genotype.  
 
3.3. Associations of APO-1/Fas (rs2234767) gene’s polymorphism with pro-
liferation and apoptosis activity in thyroid tissue 
The number of cells with receptors to Fas, FasL and Ki-67, as well as the densities of 
intracellular anti-apoptotic p53 and BCL-2 proteins and Ki-67 were reliably higher than in 
control group (p<0.019-0.001). Cell numbers figures and densities of the receptors did not 
associate directly with the polymorphic variants of the APO- 1/Fas (rs2234767) gene (table 
4). 
 
 506 
Table 4: Cell numbers and densities of the Fas, FasL, Ki-67, BCL-2, and p53 receptors 
considering the polymorphic variants of APO-1/Fas (rs2234767) gene 
Indices 
Control 
(morphologically 
unaltered thyroid 
tissue), n=25 
APO-1/Fas genotypes 
AG, n=23 GG, n=102 
Fas cells, % 0.79±0.04 17.70±4.35 
p<0.001 
18.75±4.25 
p<0.001 
Density of Fas receptors, s.u. 
13.82±0.40 7.10±1.80 
p=0.007 
10.12±1.05 
p=0.009 
FasL cells, % 3.85±0.16 7.95±1.17 
p=0.008 
7.25±1.02 
p=0.009 
Density of FasL receptors, s.u. 
11.13±0.85 10.30±1.42 10.73±1.33 
p53 cells, % 64.14±1.89 60.83±4.59 60.09±4.83 
Density of p53 protein, s.u. 
1.41±0.05 3.58±0.41 
p=0.002 
3.87±0.38 
p=0.001 
Ki-67 cells, % 
1.16±0.05 3.72±0.66 
p=0.006 
3.79±0.63 
p=0.004 
Density of Ki-67 protein, s.u. 
1.20±0.07 2.02±0.20 
p=0.006 
2.09±0.21 
p=0.005 
BCL-2 cells, % 
73.05±1.35 78.34±2.63 78.42±1.81 
p=0.02 
Density of BCL-2, s.u. 
3.86±0.16 6.49±0.63 
p=0.005 
6.70±0.58 
p=0.00no3 
Notes: 1. TG - thyroid gland; 2. p - reliability of differences between the indices as 
compared to those in the control group; pAG - reliability of differences between the indices as 
compared to those in the carriers of the AG-genotype. 
 
Univariate analysis confirmed the association of the APO-1/Fas (rs2234767) gene's 
promotor with the number of cells expressing FasL (F=8.37, p=0.005) and the density of Fas 
receptors (F=115.28, p<0.001) and intracellular protein p53 (F=10.62, p=0.001). 
 
3.4. Prediction of AIT and TA depending on BCL-2 (rs17759659), CTLA- 4 
(rs231775), and APO-1/Fas (rs2234767) genes’ polymorphisms, proliferation, and 
apoptosis activity in thyroid tissue 
High numbers of Fas, FasL, BCL-2, and Ki-67 cells, combined with decreased density 
of superficial Fas and FasL receptors, and growth of the anti-apoptotic BCL-2 protein, 
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increases the risk of thyroid pathology (AIT and TA) by 2.79 and 9 times in AG- and AA-
genotypes carriers of the BCL-2 (rs17759659) gene (OR=7.80 and OR=81.0; p<0.001), 
respectively. Combination of highly increased (>50 percentiles) Ki-67 protein density with 
reduced number of p53 containing cells and moderate reduction of BCL-2 protein (<50 
percentiles) decreases the chance of AIT and TA regardless of BCL-2 gene genotypes 
(OR=0.01; 95% CI OR: 0.001-0.23 for AA- genotype and OR=0.13; 95% CI OR: 0.07-0.23 
for AG-genotype, p<0.001, respectively). 
High content of Fas, Fas L, Ki-67, and BCL-2 expressing cells in biopsy, significant 
decrease of Fas and FasL receptors' density combined with high BCL-2 density increase the 
risk of AIT and TA by 3.92 times in AA genotype carriers of the CTLA-4 gene (OR=15.34; 
95% CI OR: 6.26-37.60; p<0.001); by 2.44 times in AG- genotype patients (OR=5.98; 95% 
CI OR: 2.75-12.98; p<0.001); by 3.08 times in homozygous wild G-allele carriers of the 
APO-1/Fas (rs2234767) gene and by 3.60 times in AG-genotype patients of the above-
mentioned gene (OR=9.49; 95% CI OR: 5.01-17.96 and OR=12,96; 95% CI OR: 3.19-52.62; 
p<0.001), respectively. 
The factors that decrease the likelihood of AIT and TA regardless of the genotypes of 
the CTLA-4 (rs231775) and APO-1/Fas (rs2234767) genes are the high Ki- 67 density and 
reduction of cells containing the proteins p53 or BCL-2 (OR=0.07-17; 95% CI OR: 0.03-0.36; 
p<0.001, and OR=0.08-0.11; 95% CI OR: 0.02-0.31; p<0.001, respectively). 
 
4. Conclusion 
In AIT and TA patients several mechanisms of thyroid cells' programmed killing are 
activated with domination of Fas-induced apoptosis, which strongly associates with the BCL-
2 gene's (rs17759659) promotor (F=25.33; p<0.001) and almost 6 times weaker associates 
with the CTLA-4 gene's (rs231775) promotor (F=4.23, p=0.017). High expression of surface 
Fas and FasL in lymphoid infiltration and destruction of thyroid cells (stronger in GG-
genotype carriers of the BCL-2 gene by 18.54% (pAA=0.043) and 36.18% (pAG=0.018), 
respectively) indicates the initiation of the external pathway of apoptosis through the caspase 
mechanism (effector caspase- 8). 
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